ERBB2 and triple-negative breast carcinoma: The immunotherapy drug pembrolizumab is recently approved for early-stage, triple-negative breast cancer (TNBC) [14], while the human epidermal growth factor receptor (HER2) inhibitor margetuximab-cmkb [15] and the antibody–drug conjugate Fam-trastuzumab deruxtecan (HER2-directed antibody which is linked to a topoisomerase inhibitor) also gained FDA approval for the treatment of HER2-positive MBC [16].